company background image
NYXH logo

Nyxoah ENXTBR:NYXH Stock Report

Last Price

€12.35

Market Cap

€354.1m

7D

-21.8%

1Y

91.2%

Updated

26 Mar, 2024

Data

Company Financials +

NYXH Stock Overview

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.

NYXH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Nyxoah S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nyxoah
Historical stock prices
Current Share Price€12.35
52 Week High€17.60
52 Week Low€3.79
Beta0.49
1 Month Change-22.57%
3 Month Change185.88%
1 Year Change91.18%
3 Year Change-36.67%
5 Year Changen/a
Change since IPO-36.67%

Recent News & Updates

Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt

Jan 24
Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt

Recent updates

Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt

Jan 24
Rock star Growth Puts Nyxoah (EBR:NYXH) In A Position To Use Debt

Do Insiders Own Lots Of Shares In Nyxoah S.A. (EBR:NYXH)?

Dec 21
Do Insiders Own Lots Of Shares In Nyxoah S.A. (EBR:NYXH)?

Shareholder Returns

NYXHBE Medical EquipmentBE Market
7D-21.8%-0.8%2.9%
1Y91.2%14.2%-1.0%

Return vs Industry: NYXH exceeded the Belgian Medical Equipment industry which returned 12.8% over the past year.

Return vs Market: NYXH exceeded the Belgian Market which returned -1.9% over the past year.

Price Volatility

Is NYXH's price volatile compared to industry and market?
NYXH volatility
NYXH Average Weekly Movement22.9%
Medical Equipment Industry Average Movement5.5%
Market Average Movement3.6%
10% most volatile stocks in BE Market7.2%
10% least volatile stocks in BE Market2.5%

Stable Share Price: NYXH's share price has been volatile over the past 3 months.

Volatility Over Time: NYXH's weekly volatility has increased from 13% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009138Olivier Taelmanhttps://www.nyxoah.com

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah S.A. Fundamentals Summary

How do Nyxoah's earnings and revenue compare to its market cap?
NYXH fundamental statistics
Market cap€354.12m
Earnings (TTM)-€43.21m
Revenue (TTM)€4.35m

81.4x

P/S Ratio

-8.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NYXH income statement (TTM)
Revenue€4.35m
Cost of Revenue€1.66m
Gross Profit€2.69m
Other Expenses€45.90m
Earnings-€43.21m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 02, 2024

Earnings per share (EPS)-1.51
Gross Margin61.91%
Net Profit Margin-993.84%
Debt/Equity Ratio8.9%

How did NYXH perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.